LG Chemical Invests in Osong Pharma Plant in South Korea

---

Researched by Industrial Info Resources (Sugar Land, Texas)--LG Chemical Limited's (Seoul, South Korea) Osong plant produces vaccines and biosimilar medicines.

From this year to around 2026, it is scheduled to expand its biosimilar production building and expand its production line for mixed vaccine raw materials for infants.

Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for related project reports.

The investment in the new vaccine line is believed to be due to LG Chem's recent participation in UNICEF's bidding and signing a total order of approximately 260 billion won ($202 million).

Based on this contract, LG Chem plans to supply vaccines to prevent infectious diseases for 80 million infants and toddlers around the world. In particular, LG Chem secured more than 30% of the total procurement volume in UNICEF's polio vaccine bidding, ranking first in orders.

Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).